DODAP (1,2-dioleoyl-3-dimethylammonium propane)

CAS Number:
Linear Formula:


Grouped product items
Catalog Number Unit Size Price QTY
14489-25 25mg
14489-100 100mg
14489-500 500mg
Save for Later
In stock
  • Key Features
  • High transfection efficiency and low cytotoxicity
  • Efficient delivery of plasmid DNA, siRNA/miRNA, and CRISPR/Cas9 components
  • Widely used in nanomedicine
  • Flexible and scalable

DODAP (1,2-dioleoyl-3-dimethylammonium-propane) is an ionizable cationic lipid with lower cytotoxicity and high transfection efficiency. DODAP is neutral at physiological pH, but acquires a positive charge inside the endosome due to the protonation of free amines when pH is lower than its pKa (<7). The electrostatic interactions between DODAP and naturally occurring anionic lipids in endosomal membranes trigger the release of nucleic acid. These interactions promote membrane lytic non-bilayer structures to enable the intracellular delivery of nucleic acid. A common application is in nanomedicine as an ionizable lipid component of nanocarriers (lipid-polymer hybrid nanoparticles, LPNs), widely used to encapsulate bioactive molecules, including mRNA, siRNA, and plasmid DNA as a treatment for diseases.

Contact us at [email protected] to know about our cGMP grade DODAP manufactured under 21 CFR part 210,211.

DNA, SiRNA, mRNA transfection, Drug delivery, Gene therapy
Shipping Requirements:
Dry Ice
Colorless to light yellow liquid
Molecular Weight:

Fattore, L., Campani, V., Ruggiero, C.F., Salvati, V., Liguoro, D., Scotti, L., Botti, G., Ascierto, P.A., Mancini, R., De Rosa, G., Ciliberto, G. (2020). In Vitro Biophysical and Biological Characterization of Lipid Nanoparticles Co-Encapsulating Oncosuppressors miR-199b-5p and miR-204-5p as Potentiators of Target Therapy in Metastatic Melanoma. Int J Mol Sci. 12;21(6):1930.

Granot, Y., & Peer, D. (2017). Delivering the right message: Challenges and opportunities in lipid nanoparticles-mediated modified mRNA therapeutics-An innate immune system standpoint. Semin Immunol. 34:68-77.

Pardi, N., Hogan, M.J., Porter, F.W., Weissman, D. (2018). mRNA vaccines -- a new era in vaccinology. Nat. Rev. Drug Discov. 17:261 -279.

Herrington, T., Patlolla, R., & Altin, J. (2009). Targeting of plasmid DNA-lipoplexes to cells with molecules anchored via a metal chelator lipid. J. Gene Med. 11(11): 1048-63.

Sahin, U., Karikó, K., Türeci, Ö. (2014). mRNA-based therapeutics -- developing a new class of drugs. Nat. Rev. Drug Discov. 13:759 -780.

Semple, S., Klimuk, S., Harasym, T., Dos Santos, N., Ansell, S., Wong, K., Maurer, N., Stark, H., Cullis, P., Hope, M., & Scherrer, P. (2001). Efficient encapsulation of antisense oligonucleotides in lipid vesicles using ionizable aminolipids: formation of novel small multilamellar vesicle structures. Biochemimica et Biophysica Acta. 1510(1-2): 152-166.

Protective gloves, safety glasses
Userway Icon